AIMS: Therapeutic drug monitoring (TDM) of tacrolimus is complicated by conflicting data on the correlation between tacrolimus trough blood concentrations and the incidence of rejection. The aim of this cross-sectional study was to investigate the blood distribution and protein binding of tacrolimus in liver transplant recipients to explore better predictors of clinical outcome. METHODS: Blood and plasma distribution of 3H-dihydro-tacrolimus was investigated in 40 liver transplant recipients using Ficoll Paque and density gradient ultracentrifugation, respectively, and equilibrium dialysis to investigate plasma protein binding. RESULTS: In blood tacrolimus was mainly associated with the erythrocyte fraction (83.2%, range 74.6-94.9%), followed by diluted plasma (16.1%, range 4.5-24.9%), and lymphocyte fraction (0.61%, range: 0.11-1.53%). In plasma, lipoprotein deficient serum fraction (54.2%, range 38.5-68.2%) was the main reservoir of tacrolimus. The unbound fraction of tacrolimus was found to be 0.47 +/- 0.18% (range 0.07-0.89%). The percentage of tacrolimus associated with the lymphocytes (0.8 +/- 0.4 vs 0.3 +/- 0.1%, P = 0.012) and estimated unbound concentration (0.42 +/- 0.21 ng l-1vs 0.24 +/- 0.08 ng l-1, P < 0.001) of tacrolimus were significantly different in stable transplant recipients and those experiencing rejection. Haematocrit and red blood cell count significantly influenced the percentage of tacrolimus associated with erythrocytes. The fraction unbound of tacrolimus was correlated with alpha1-acid glycoprotein and high density lipoprotein cholesterol concentrations. CONCLUSIONS: Tacrolimus unbound concentration was observed to be lower in liver transplant recipients experiencing rejection and further study is required to evaluate its utility in the TDM of tacrolimus.
AIMS: Therapeutic drug monitoring (TDM) of tacrolimus is complicated by conflicting data on the correlation between tacrolimus trough blood concentrations and the incidence of rejection. The aim of this cross-sectional study was to investigate the blood distribution and protein binding of tacrolimus in liver transplant recipients to explore better predictors of clinical outcome. METHODS: Blood and plasma distribution of 3H-dihydro-tacrolimus was investigated in 40 liver transplant recipients using Ficoll Paque and density gradient ultracentrifugation, respectively, and equilibrium dialysis to investigate plasma protein binding. RESULTS: In blood tacrolimus was mainly associated with the erythrocyte fraction (83.2%, range 74.6-94.9%), followed by diluted plasma (16.1%, range 4.5-24.9%), and lymphocyte fraction (0.61%, range: 0.11-1.53%). In plasma, lipoprotein deficient serum fraction (54.2%, range 38.5-68.2%) was the main reservoir of tacrolimus. The unbound fraction of tacrolimus was found to be 0.47 +/- 0.18% (range 0.07-0.89%). The percentage of tacrolimus associated with the lymphocytes (0.8 +/- 0.4 vs 0.3 +/- 0.1%, P = 0.012) and estimated unbound concentration (0.42 +/- 0.21 ng l-1vs 0.24 +/- 0.08 ng l-1, P < 0.001) of tacrolimus were significantly different in stable transplant recipients and those experiencing rejection. Haematocrit and red blood cell count significantly influenced the percentage of tacrolimus associated with erythrocytes. The fraction unbound of tacrolimus was correlated with alpha1-acid glycoprotein and high density lipoprotein cholesterol concentrations. CONCLUSIONS:Tacrolimus unbound concentration was observed to be lower in liver transplant recipients experiencing rejection and further study is required to evaluate its utility in the TDM of tacrolimus.
Authors: L Bäckman; M Nicar; M Levy; D Distant; C Eisenstein; T Renard; R Goldstein; B Husberg; T Gonwa; G Klintmalm Journal: Transplant Proc Date: 1994-06 Impact factor: 1.066
Authors: R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl Journal: Clin Pharmacokinet Date: 1995-12 Impact factor: 6.447
Authors: W J Jusko; W Piekoszewski; G B Klintmalm; M S Shaefer; M F Hebert; A A Piergies; C C Lee; P Schechter; Q A Mekki Journal: Clin Pharmacol Ther Date: 1995-03 Impact factor: 6.875
Authors: Itziar Oteo; John C Lukas; Nerea Leal; Elena Suarez; Andres Valdivieso; Mikel Gastaca; Jorge Ortiz de Urbina; Rosario Calvo Journal: Eur J Clin Pharmacol Date: 2012-06-03 Impact factor: 2.953
Authors: Rogier R Press; Bart A Ploeger; Jan den Hartigh; T van der Straaten; Hans van Pelt; Meindert Danhof; Hans de Fijter; Henk-Jan Guchelaar Journal: Eur J Clin Pharmacol Date: 2010-03-31 Impact factor: 2.953
Authors: Mary F Hebert; Songmao Zheng; Karen Hays; Danny D Shen; Connie L Davis; Jason G Umans; Menachem Miodovnik; Kenneth E Thummel; Thomas R Easterling Journal: Transplantation Date: 2013-04-15 Impact factor: 4.939
Authors: Songmao Zheng; Thomas R Easterling; Karen Hays; Jason G Umans; Menachem Miodovnik; Shannon Clark; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert Journal: Br J Clin Pharmacol Date: 2013-12 Impact factor: 4.335
Authors: Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt Journal: Clin Pharmacokinet Date: 2016-09 Impact factor: 6.447
Authors: Songmao Zheng; Thomas R Easterling; Jason G Umans; Menachem Miodovnik; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert Journal: Ther Drug Monit Date: 2012-12 Impact factor: 3.681